prof. dr. Jo Lambert
- ORCID iD
- 0000-0001-5303-9310
Show
Sort by
-
- Journal Article
- A1
- open access
Determining patient value profiles in psoriasis
-
- Journal Article
- A1
- open access
Value in psoriasis (IRIS) trial : implementing value-based healthcare in psoriasis management : a 1-year prospective clinical study to evaluate feasibility and value creation
-
- Journal Article
- A1
- open access
Blocking interleukin-17 in psoriasis : real-world experience from the PsoPlus cohort
-
- Journal Article
- A1
- open access
SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders : a prospective, real-life Belgian cohort study - the BELCOMID study
-
- Journal Article
- A1
- open access
PsoPlus : an integrated practice unit for psoriasis
-
- Journal Article
- A1
- open access
Initiating value‐based healthcare in psoriasis : proposing a value‐based outcome set for daily clinical practice
-
- Journal Article
- A1
- open access
Adalimumab with methotrexate vs. adalimumab monotherapy in psoriasis : first-year results of a single-blind randomized controlled trial
-
Credibility and generalization of the minimally important difference concept in dermatology : a scoping review
-
Therapeutic drug monitoring of biologics in inflammatory bowel disease : unmet needs and future perspectives
-
- Journal Article
- A1
- open access
Variability drivers of treatment costs in hospitals : a systematic review
-
- Journal Article
- A1
- open access
Real-life effectiveness of apremilast for the treatment of psoriasis in Belgium : results from the observational OTELO study
-
- Journal Article
- A1
- open access
Promising tools to facilitate the implementation of TDM of biologics in clinical practice
-
Patient-relevant outcomes in psoriasis : a systematic review
-
International eDelphi study to reach consensus on the methotrexate dosing regimen in patients with psoriasis
-
- Journal Article
- A1
- open access
Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic : findings from a global patient-reported cross-sectional survey
-
Weighing in on weight‐based secukinumab dosing for psoriasis
-
- Journal Article
- A1
- open access
Long‐term efficacy and safety of brodalumab in moderate‐to‐severe plaque psoriasis : a post hoc pooled analysis of AMAGINE‐2 and ‐3
-
- Journal Article
- A1
- open access
Freedom from disease in psoriasis : a Delphi consensus definition by patients, nurses and physicians
-
The effects of Modified Intermittent Fasting in Psoriasis (MANGO) : preliminary results of a pilot crossover study
-
Defining value for patients with psoriasis : development of a patient-driven outcome set for clinical practice
-
- Journal Article
- A1
- open access
Therapeutic drug monitoring in dermatology : the way towards dose optimization of secukinumab in chronic plaque psoriasis
-
Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis : results of a structured survey
-
- Journal Article
- A2
- open access
The effects of Modified Intermittent Fasting in Psoriasis (MANGO) trial : a two-arm pilot randomized controlled open cross-over study
-
- Journal Article
- A1
- open access
Venous thrombotic events in psoriasis patients : a systematic review with meta-analysis
-
- Journal Article
- A2
- open access
The use of metrics in daily practice and the perception of psoriasis-associated comorbidities : discrepancies between research and real-world
-
Alopecia areata : a review on diagnosis, immunological etiopathogenesis and treatment options
-
- Journal Article
- A1
- open access
Personalized development of antisense oligonucleotides for exon skipping restores type XVII collagen expression in junctional epidermolysis bullosa
-
Factors associated with adverse COVID-19 outcomes in patients with psoriasis : insights from a global registry–based study
-
- Journal Article
- A1
- open access
Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis : study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study : the BeNeBio study
-
Describing the burden of the COVID‐19 pandemic in people with psoriasis : findings from a global cross‐sectional study
-
- Journal Article
- A1
- open access
Dermatology life quality index in patients with moderate-to-severe plaque psoriasis treated with Brodalumab or Ustekinumab
-
- Journal Article
- A1
- open access
Cutaneous manifestations in biological-treated inflammatory bowel disease patients : a narrative review
-
- Journal Article
- A1
- open access
Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type : a cross‐sectional patient survey
-
Comment on 'An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology'
-
Interim results of the MANGO trial : modified intermittent fasting in psoriasis
(2021) JOURNAL OF INVESTIGATIVE DERMATOLOGY. In Journal of Investigative Dermatology 141(10). p.S190-S190 -
Creating value for psoriasis patients : development of a patient-driven outcome set for clinical practice
(2021) JOURNAL OF INVESTIGATIVE DERMATOLOGY. In Journal of Investigative Dermatology 141(10). p.S160-S160 -
- Journal Article
- A1
- open access
Vaccinations in patients receiving systemic drugs for skin disorders : what can we learn for SARS-Cov-2 vaccination strategies?
-
First results of the BELCOMID study : Belgian cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
-
- Journal Article
- A2
- open access
Effectiveness and tolerability of guselkumab in patients with psoriasis : a longitudinal Belgian retrospective multicenter study
-
The reliability of the Self-Assessment Cutaneous Inflammatory Disease Extent Score (SA-CIDES) and the rule of hands to assess the involved body surface area in psoriasis and eczema
-
- Journal Article
- A1
- open access
The implementation of a structured specialized consultation for psoriasis management
-
- Journal Article
- A1
- open access
Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis : the UltIMMa-1 and UltIMMa-2 randomized clinical trials
-
- Journal Article
- A1
- open access
Autoimmunity in segmental vitiligo
-
- Journal Article
- A1
- open access
Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)
-
- Journal Article
- A1
- open access
Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1)
-
Real‐life effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis : a Belgian retrospective multicentre study
-
Teledermatology in Belgium : a pilot study
-
- Journal Article
- A1
- open access
Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy : an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
-
- Journal Article
- A1
- open access
Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene : results from a multicentre study of four European psoriasis cohorts
-
- Journal Article
- A1
- open access
A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents
-
Comparison of personality traits among patients with psoriasis, atopic dermatitis, and stress: a pilot study
-
- Journal Article
- A1
- open access
A Belgian consensus on the definition of a treat‐to‐target outcome set in psoriasis management
-
- Journal Article
- A1
- open access
Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis
-
- Journal Article
- A1
- open access
Defining a minimal effective serum trough concentration of secukinumab in psoriasis : a step toward personalized therapy
-
Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases
-
Therapeutische Patientenschulungsprogramme und Unterstützung beim Selbstmanagement für Patienten mit Psoriasis : eine systematische Übersicht
-
Tasks, competences and educational needs of dermatology healthcare providers in the public and private sectors : results of the EADV-NWAG survey in Belgium
-
Periocular contact allergy from spectacle frames cleaned with methylisothiazolinone‐containing household detergents
-
- Journal Article
- A1
- open access
Learning from success and failure: biologics for non-approved skin diseases
-
- Journal Article
- A1
- open access
Clinical consequences of antibody formation, serum concentrations, and HLA-Cw6 status in psoriasis patients on Ustekinumab
-
Comparison of methods to estimate the affected body surface area and the dosage of topical treatments in psoriasis and atopic dermatitis : the advantage of a picture‐based tool
-
Therapeutic patient education and self‐management support for patients with psoriasis : a systematic review
-
Developing a therapeutic window for secukinumab in psoriasis : a step towards personalized therapy
-
Microbial transplant to shift a malodorous armpit microbiome
-
Developing a therapeutic window for secukinumab in psoriasis : a step towards personalized therapy
-
Targeting the IL-23/IL-17 pathway in psoriasis : the search for the good, the bad and the ugly
-
Critical appraisal of the oxidative stress pathway in vitiligo : a systematic review and meta-analysis
-
Towards the development of a RNAi-based topical treatment for psoriasis : proof-of-concept in a 3D psoriasis skin model
-
Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis
-
Role of the HLA-C*06 allele in clinical response to ustekinumab : evidence from real life in a large cohort of European patients
-
Topically applied lipid- and surfactant-based nanoparticles in the treatment of skin disorders
-
In vitro psoriasis models with focus on reconstructed skin models as promising tools in psoriasis research
-
Safety of systemic agents for the treatment of pediatric psoriasis
-
Secukinumab : IL-17A inhibition to treat psoriatic arthritis
-
Treatment patterns in moderate-to-severe plaque psoriasis : results from a Belgian cross-sectional study (DISCOVER)
-
Towards a bacterial treatment for armpit malodour
-
Dienst Dermatologie UZ Gent wordt beloond voor inzet in de zorg voor psoriasis
-
Laat wat van je horen
-
Elevated ΔNp63α levels facilitate epidermal and biliary oncogenic transformation
-
Chronic and invasive fungal infections in a family with CARD9 deficiency (vol 36, pg 204, 2016)
-
Contact dermatitis in patients undergoing serial intravitreal injections
-
FRT - Fondation René Touraine : an international foundation for dermatology
-
- Journal Article
- A1
- open access
JAK3 as an emerging target for topical treatment of inflammatory skin diseases
-
Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants
-
Je hebt psoriasis... maar ken je psoriasis?
-
Clinical significance of serum soluble CD molecules to assess disease activity in vitiligo
-
Measuring the impact of vitiligo : behind the white spots
-
Analysis of telomere length as predictive marker in psoriasis for comorbidities
-
Global survey into the use of therapeutic patient education during psoriasis management
-
Pyoderma gangrenosum with granuloma formation: not always a benign disorder
-
A multileveled approach in psoriasis assessment and follow-up : a proposal for a tailored guide for the dermatological practice
-
Psoriasis : burning down the host
-
Exploring the feasibility of whole blood to identify systemic miRNA biomarkers for patients with moderate-to-severe psoriasis
-
Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis : a Belgian perspective
-
- Journal Article
- A2
- open access
Characterization data on the topical carrier DDC642
-
The many faces of interleukin-17 in inflammatory skin diseases
-
Chronic and invasive fungal infections in a family with CARD9 deficiency
-
An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: proof-of-concept in the treatment of psoriasis
-
Effects of apremilast on pruritus in patients with moderate to severe plaque psoriasis : results from the ESTEEM 1 and 2 trials
-
microRNAs in psoriasis: leaders or followers?